RxDoctor Payments Data

David Tabor, DO

Internal Medicine · Wyoming, MINPI 1720097231

Payments from drug & device makers

$4,354in general payments, 2019–2025

Across 364 payments — averaging $11.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$886
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$785
  • Takeda Pharmaceuticals U.S.A., Inc.$650
  • Johnson & Johnson$433
  • Bristol Myers Squibb$231
  • Gilead$136
  • plus $1K from 27 others

What the payments were for

  • Food & beverage$4,21597%
  • Education$1393%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,354 in reported general payments places this provider in the 85th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$152,030
Medicare patients
186
Services billed
5,776

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab27$183,276
RinvoqUpadacitinib18$137,269
LinzessLinaclotide159$112,036
CreonLipase/Protease/Amylase42$102,490
ZenpepLipase/Protease/Amylase22$75,067
Ursodiol47$19,425
Budesonide DrBudesonide66$18,474
Mesalamine41$18,228
MotegrityPrucalopride Succinate16$14,909
Mesalamine ErMesalamine22$13,497
OzempicSemaglutide13$12,385
Colestipol Hcl79$9,099
Lubiprostone38$8,885
Balsalazide Disodium29$8,325
Dexlansoprazole DrDexlansoprazole22$6,934

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Linzess, Creon$886$351,794219 claims
Aimmune Therapeutics, Inc.Zenpep$21$75,06722 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$650$14,90916 claims
SandozLansoprazole$14$53015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Wyoming

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →